Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Omigapil maleate

EU orphan designation number: EU/3/08/544   
Active ingredient: Omigapil maleate
Indication: Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency
Sponsor: Santhera Pharmaceuticals (Deutschland) GmbH
Wallbrunnstrasse 24, D-79539 Lörrach, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
14/05/2008 Centralised Orphan - Designation EMEA/OD/009/08 (2008)1897 of 08/05/2008